Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of a 3-Dose Schedule of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Trial Profile

Safety and Immunogenicity of a 3-Dose Schedule of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Diphtheria tetanus and pertussis vaccine; Haemophilus vaccines; Hepatitis B vaccine; Influenza B virus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal vaccine conjugate; Poliovirus vaccine; Rotavirus vaccine; Varicella zoster virus vaccine
  • Indications Meningococcal infections
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 24 Oct 2018 Planned End Date changed from 1 May 2020 to 3 Nov 2020.
    • 24 Oct 2018 Planned primary completion date changed from 1 May 2020 to 3 Nov 2020.
    • 21 Sep 2018 Planned initiation date changed from 17 Aug 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top